Molecular Oncology
Volume 4, Issue 4 , Pages 357-368 , August 2010

Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer

  • Aslaug Aamodt Muggerud

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, 0310 Oslo, Norway
    • Institute of Clinical Medicine, University of Oslo, Norway
    • Present address: Oslo MS Genetics Group, Department of Neurology, Oslo University Hospital and University of Oslo, Oslo, Norway.
    • ,
  • Michael Hallett

      Affiliations

    • McGill Centre for Bioinformatics, McGill University, Québec, Canada
    • Goodman Cancer Centre, McGill University, Québec, Canada
    • ,
  • Hilde Johnsen

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, 0310 Oslo, Norway
    • ,
  • Kristine Kleivi

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, 0310 Oslo, Norway
    • Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland
    • ,
  • Wenjing Zhou

      Affiliations

    • Department of Surgery, Uppsala University Hospital, Sweden
    • ,
  • Simin Tahmasebpoor

      Affiliations

    • Department of Genetics and Pathology, Uppsala University Hospital, Sweden
    • ,
  • Rose-Marie Amini

      Affiliations

    • Department of Oncology and Pathology, Karolinska University Hospital, Sweden
    • ,
  • Johan Botling

      Affiliations

    • Department of Genetics and Pathology, Uppsala University Hospital, Sweden
    • ,
  • Anne-Lise Børresen-Dale

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, 0310 Oslo, Norway
    • Institute of Clinical Medicine, University of Oslo, Norway
    • ,
  • Therese Sørlie

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, 0310 Oslo, Norway
    • Department of Informatics, University of Oslo, Norway
    • Corresponding Author InformationCorresponding author. Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, 0310 Oslo, Norway. Tel.: +47 22781364; fax: +47 22781395.
    • ,
  • Fredrik Wärnberg

      Affiliations

    • Department of Surgery, Uppsala University Hospital, Sweden

Received 29 April 2010 ,Revised 14 June 2010 ,Accepted 17 June 2010.

References 

  1. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin. Cancer Res. 2008;14:370–378
  2. Bethwaite P, Smith N, Delahunt B, Kenwright D. Reproducibility of new classification schemes for the pathology of ductal carcinoma in situ of the breast. J. Clin. Pathol. 1998;51:450–454
  3. Bhati R, Patterson C, Livasy CA, Fan C, Ketelsen D, Hu Z, et al. Molecular characterization of human breast tumour vascular cells. Am. J. Pathol. 2008;172:1381–1390
  4. Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, Neve RM, et al. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin. Exp. Metastasis. 2008;25:629–642
  5. Casey T, Bond J, Tighe S, Hunter T, Lintault L, Patel O, et al. Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Res. Treat. 2009;114:47–62
  6. Celis JE, Gromova I, Cabezon T, Gromov P, Shen T, Timmermans-Wielenga V, et al. Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Mol. Oncol. 2007;1:321–349
  7. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumours and wounds. PLoS Biol. 2004;2:E7
  8. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses’ Health Study. Cancer. 2005;103:1778–1784
  9. Cuzick J. Treatment of DCIS–results from clinical trials. Surg. Oncol. 2003;12:213–219
  10. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:P3
  11. Elston EW, Ellis IO. Method for grading breast cancer. J. Clin. Pathol. 1993;46:189–190
  12. Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, et al. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol. 2006;45:536–543
  13. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin. Oncol. 2001;28:400–418
  14. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80
  15. Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res. 2006;8:R61
  16. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin. Diagn. Pathol. 1994;11:167–180
  17. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362:95–102
  18. Hu M, Polyak K. Microenvironmental regulation of cancer development. Curr. Opin. Genet. Dev. 2008;18:27–34
  19. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008;13:394–406
  20. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, et al. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J. Cell Physiol. 2007;213:374–383
  21. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15
  22. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249–264
  23. Jechlinger M, Grunert S, Tamir IH, Janda E, Ludemann S, Waerner T, et al. Expression profiling of epithelial plasticity in tumour progression. Oncogene. 2003;22:7155–7169
  24. Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer. 1982;50:1309–1314
  25. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J. Natl. Cancer Inst. 2004;96:906–920
  26. Lien HC, Hsiao YH, Lin YS, Yao YT, Juan HF, Kuo WH, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial–mesenchymal transition. Oncogene. 2007;26:7859–7871
  27. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, et al. Gene expression profiles of human breast cancer progression. Proc. Natl. Acad. Sci. U S A. 2003;100:5974–5979
  28. Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol. Oncol. 2007;1:160–171
  29. Navin N, Hicks J. Tracing the tumour lineage. Mol. Oncol. 2010;4:267–283
  30. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009;27:1160–1167
  31. Patani N, Cutuli B, Mokbel K. Current management of DCIS: a review. Breast Cancer Res. Treat. 2008;111:1–10
  32. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752
  33. Polyak K, Hu M. Do myoepithelial cells hold the key for breast tumour progression?. J. Mammary Gland Biol. Neoplasia. 2005;10:231–247
  34. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol. Cancer Res. 2003;1:362–375
  35. Rice A, Quinn CM. Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast. J. Clin. Pathol. 2002;55:569–574
  36. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial–mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68:989–997
  37. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumours, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res. 2006;66:5278–5286
  38. Sharma M, Beck AH, Webster JA, Espinosa I, Montgomery K, Varma S, et al. Analysis of stromal signatures in the tumour microenvironment of ductal carcinoma in situ. Breast Cancer Res. Treat. 2009;
  39. Smyth GK, Speed T. Normalization of cDNA microarray data. Methods. 2003;31:265–273
  40. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc. Natl. Acad. Sci. U S A. 2001;98:10869–10874
  41. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumour subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U S A. 2003;100:8418–8423
  42. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U S A. 2005;102:15545–15550
  43. Teo NB, Shoker BS, Jarvis C, Martin L, Sloane JP, Holcombe C. Angiogenesis and invasive recurrence in ductal carcinoma in situ of the breast. Eur. J. Cancer. 2003;39:38–44
  44. Tlsty TD, Hein PW. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev. 2001;11:54–59
  45. Turley EA, Veiseh M, Radisky DC, Bissell MJ. Mechanisms of disease: epithelial–mesenchymal transition – does cellular plasticity fuel neoplastic progression?. Nat. Clin. Pract. Oncol. 2008;5:280–290
  46. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U S A. 2001;98:5116–5121
  47. van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536
  48. Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, Goudefroye R, et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin. Cancer Res. 2008;14:1956–1965
  49. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365:671–679
  50. West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL, Rubin BP, et al. Determination of stromal signatures in breast carcinoma. PLoS Biol. 2005;3:e187
  51. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, et al. Changes in cytoskeletal protein composition indicative of an epithelial–mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin. Cancer Res. 2005;11:8006–8014
  52. Yu M, Tang Z, Alousi S, Berk RS, Miller F, Kosir MA. Expression patterns of lymphangiogenic and angiogenic factors in a model of breast ductal carcinoma in situ. Am. J. Surg. 2007;194:594–599

PII: S1574-7891(10)00059-1

doi: 10.1016/j.molonc.2010.06.007

Molecular Oncology
Volume 4, Issue 4 , Pages 357-368 , August 2010

Article Tools

* Image Usage & Resolution